Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: Trends over time in a European randomized trial

BJU International

Volumn 110, Issue 11, 2012, Pages 1654-1660

  Bokhorst, Leonard P ^a   Zhu, Xiaoye ^a   Bul, Meelan ^a   Bangma, Chris H ^a   Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

biopsy; positive predictive value; predictive value of tests; prostate specific antigen; prostatic neoplasms; PSA; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE;

EID: 84870955651     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11481.x     Document Type: Article

References (34)

1. Catalona WJ, Smith DS, Ratliff TL, et al,. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
2. Schroder FH, Hugosson J, Roobol MJ, et al,. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90
3. Thompson IM, Ankerst DP, Chi C, et al,. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70
4. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
5. Schroder FH, Denis L, Roobol MJ,. Epilogue: different approaches for prostate cancer screening in the EU? Eur J Cancer 2010; 46: 3120-5
6. Schroder F, Kattan MW,. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008; 54: 274-90
7. Roobol MJ, van Vugt HA, Loeb S, et al,. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012; 61: 577-83
8. Kranse R, Roobol M, Schroder FH,. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008; 68: 1674-80
9. Roobol MJ, Kirkels WJ, Schroder FH,. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92 (Suppl. 2): 48-54
10. Eskew LA, Bare RL, McCullough DL,. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202; discussion 202-3
11. Chou R, Croswell JM, Dana T, et al,. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011; 155: 762-71
12. Moyer VA, on behalf of the USPSTF. Screening for Prostate Cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-34
13. Djulbegovic M, Beyth RJ, Neuberger MM, et al,. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543
14. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ,. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 110-4
15. Gann PH, Hennekens CH, Stampfer MJ,. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
16. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB,. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 411-6
17. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
18. Raaijmakers R, Blijenberg BG, Finlay JA, et al,. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004; 171: 2245-9
19. van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH,. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95: 1462-6
20. Zhu X, van Leeuwen PJ, Bul M, et al,. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up. Eur Urol 2011; 60: 330-6
21. Otto SJ, Moss SM, Maattanen L, et al,. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 3053-60
22. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ,. Risk-based prostate cancer screening. Eur Urol 2012; 61: 652-61
23. Hoeks CM, Barentsz JO, Hambrock T, et al,. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66
24. Hoeks CM, Schouten MG, Bomers JG, et al,. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012; [Epub ahead of print]
25. Schröder FH, van den Bergh RC, Wolters T, et al,. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010; 57: 258-66
26. Garzotto M, Hudson RG, Peters L, et al,. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003; 98: 1417-22
27. Makarov DV, Loeb S, Getzenberg RH, Partin AW,. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139-51
28. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M,. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 2010; 58: 551-8
29. Trottier G, Roobol MJ, Lawrentschuk N, et al,. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. BJU Int 2011; 108: E237-44
30. Alibhai SM, Krahn MD, Fleshner NE, Cohen MM, Tomlinson GA, Naglie G,. The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int 2004; 94: 303-6
31. Cremers RG, Karim-Kos HE, Houterman S, et al,. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006. Eur J Cancer 2010; 46: 2077-87
32. Boevee SJ, Venderbos LD, Tammela TL, et al,. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 3082-9
33. Gosselaar C, Roobol MJ, Roemeling S, et al,. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 2006; 66: 625-31
34. Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schroder FH,. Digital rectal examination and the diagnosis of prostate cancer-a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol 2009; 55: 139-46